The effect of Montelukast on the treatment of diarrhea and vomiting in children

The effect of Montelukast on gastroenteritis-induced azotemia in children admitted to Amirkabir Hospital

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201005048940N1

Enrollment

Registered

2020-10-08

Start date

2020-10-10

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroenteritis. Allergic and dietetic gastroenteritis and colitis

Interventions

Intervention 1: Intervention group: Prescribing 5mg of Montelukast made by Obaidi company for 5 days and once a day to this group. Intervention 2: Control group: Do not prescribe Montelukast to this g

Eligibility

Sex/Gender

All

Age

3 Years to 18 Years

Inclusion criteria

Inclusion criteria: Satisfaction of the person to enter the study GFR < 90 All hospitalized children over 3 years with moderate gastroenteritis symptoms Absence of chronic disease

Exclusion criteria

Exclusion criteria: Lack of cooperation during the study Intolerance to medication Inability to swallow pills Allergy to the drug Montelukast

Design outcomes

Primary

Measure	Time frame
GFR recovery time. Timepoint: daily. Method of measurement: Using laboratory Bun, Cr and GFR calculation formulas.;Duration of improvement of dehydration symptoms. Timepoint: daily. Method of measurement: By performing a clinical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzane Moradi Shamami

Arak University of Medical Sciences

f.moradi88@yahoo.com+98 86 3313 4715

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026